By Scientia Professor Vlado Perkovic

Journal articles

Jun M; Jardine MJ; Perkovic V; Pilard Q; Billot L; Rodgers A; Rogers K; Gallagher M, 2019, 'Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study', PLoS ONE, 14, pp. e0213192, http://dx.doi.org/10.1371/journal.pone.0213192

Coresh J; Heerspink HJL; Sang Y; Matsushita K; Arnlov J; Astor BC; Black C; Brunskill NJ; Carrero JJ; Feldman HI; Fox CS; Inker LA; Ishani A; Ito S; Jassal S; Konta T; Polkinghorne K; Romundstad S; Solbu MD; Stempniewicz N; Stengel B; Tonelli M; Umesawa M; Waikar SS; Wen CP; Wetzels JFM; Woodward M; Grams ME; Kovesdy CP; Levey AS; Gansevoort RT; Appel LJ; Greene T; Chen TK; Chalmers J; Arima H; Perkovic V; Levin A; Djurdjev O; Tang M; Nally J; Navaneethan SD; Schold JD; Weldegiorgis M; Herrington WG; Smith M; Hsu CY; Hwang SJ; Chang AR; Kirchner HL; Green JA; Ho K; Marks A; Prescott G; Clark LE; Fluck N; Shalev V; Chodick G; Blankestijn PJ; Van Zuilen A; Van den Brand JA; Sarnak MJ; Bottinger E; Nadkarni GN; Ellis SG; Nadukuru R; Metzger M; Flamant M; Houillier P; Haymann JP; Froissart M; Kenealy T; Elley RC; Collins JF; Drury PL; Cuddeback JK; Ciemins EL; Stempniewicz R; Nelson RG; Knowler WC; Bakker SJ; Major RW; Medcalf JF; Shepherd D; Barrett-Connor E; Bergstrom J; Ix JH; Molnar MZ; Sumida K; de Zeeuw D; Brenner B; Qureshi AR; Elinder CG; Runesson B; Evans M; Segelmark M; Stendahl M; Schön S; Naimark DM; Tangri N, 2019, 'Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies', The Lancet Diabetes and Endocrinology, 7, pp. 115 - 127, http://dx.doi.org/10.1016/S2213-8587(18)30313-9

Heerspink HJL; Greene T; Tighiouart H; Gansevoort RT; Coresh J; Simon AL; Chan TM; Hou FF; Lewis JB; Locatelli F; Praga M; Schena FP; Levey AS; Inker LA; Sevillano A; Kamper AL; van Zuilen AD; Brenner BM; Maes B; Ihle BU; Barret B; Leung CB; Szeto CC; Fitzner C; Wanner C; Pozzi C; Montagnino CP; Xie D; de Zeeuw D; Lewis E; Verde E; Gutierrez E; Imai E; Caravaca F; Fervenza FC; Kobayashi F; Moroni G; Becker GJ; Beck GJ; Appel GB; Frisch G; van Essen GG; Maschio G; Remuzzi G; Montogrino G; Parving HH; Heerspink HJL; Makino H; Jehan I; Wetzels JFM; Donadio J; Dwyer J; van den Brand J; Kusek J; Lachin JM; Luño J; Lewis JB; Floege J; Abebe KZ; Chow KM; Hunsicker LG; del Vecchio L; Carlo M; Goicoechea M; von Eynatten M; Poulter N; Chaturvedi N; Passerini P; de Jong PE; Blankestijn PJ; Li P; Ruggenenti P; Zucchelli P; Kincaid-Smith PS; Hilgers RD; Estacio RO; Rohde RD; Katafuchi R; Toto RD; Schrier RW; Rodby RA; Perrone RD; Ito S; Klahr S; Andrulli S; Strandgaard S; Hannedouche TP; Rauen T; Verdalles U; Perkovic V; Keane W, 2019, 'Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials', The Lancet Diabetes and Endocrinology, 7, pp. 128 - 139, http://dx.doi.org/10.1016/S2213-8587(18)30314-0

Inker LA; Grams ME; Levey AS; Coresh J; Cirillo M; Collins JF; Gansevoort RT; Gutierrez OM; Hamano T; Heine GH; Ishikawa S; Jee SH; Kronenberg F; Landray MJ; Miura K; Nadkarni GN; Peralta CA; Rothenbacher D; Schaeffner E; Sedaghat S; Shlipak MG; Zhang L; van Zuilen AD; Hallan SI; Kovesdy CP; Woodward M; Levin A; Astor B; Appel L; Greene T; Chen T; Chalmers J; Arima H; Perkovic V; Yatsuya H; Tamakoshi K; Li Y; Hirakawa Y; Matsushita K; Sang Y; Polkinghorne K; Chadban S; Atkins R; Djurdjev O; Liu L; Zhao M; Wang F; Wang J; Ebert N; Martus P; Tang M; Emrich I; Seiler S; Zawada A; Nally J; Navaneethan S; Schold J; Sarnak M; Katz R; Hiramoto J; Iso H; Yamagishi K; Umesawa M; Muraki I; Fukagawa M; Maruyama S; Hasegawa T; Fujii N; Wheeler D; Emberson J; Townend J; Brenner H; Schöttker B; Saum KU; Fox C; Hwang SJ; Köttgen A; Schneider MP; Eckardt KU; Green J; Kirchner HL; Chang AR; Ho K; Ito S; Miyazaki M; Nakayama M; Yamada G; Irie F; Sairenchi T; Yano Y; Kotani K; Nakamura T; Kimm H; Mok Y; Chodick G; Shalev V; Wetzels JFM; Blankestijn PJ; van den Brand J; Kollerits B, 2019, 'Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium', American Journal of Kidney Diseases, 73, pp. 206 - 217, http://dx.doi.org/10.1053/j.ajkd.2018.08.013

McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; Von Eynatten M; Marx N, 2019, 'Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA', Circulation, 139, pp. 351 - 361, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038352

Ohkuma T; Jun M; Rodgers A; Cooper ME; Glasziou P; Hamet P; Harrap S; Mancia G; Marre M; Neal B; Perkovic V; Poulter N; Williams B; Zoungas S; Chalmers J; Woodward M, 2019, 'Acute Increases in Serum Creatinine after Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial', Hypertension, 73, pp. 84 - 91, http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.12060

Chang AR; Grams ME; Ballew SH; Bilo H; Correa A; Evans M; Gutierrez OM; Hosseinpanah F; Iseki K; Kenealy T; Klein B; Kronenberg F; Lee BJ; Li Y; Miura K; Navaneethan SD; Roderick PJ; Valdivielso JM; Visseren FLJ; Zhang L; Gansevoort RT; Hallan SI; Levey AS; Matsushita K; Shalev V; Woodward M; Chalmers J; Perkovic V, 2019, 'Adiposity and risk of decline in glomerular filtration rate: Meta-analysis of individual participant data in a global consortium', BMJ (Online), 364, pp. k5301, http://dx.doi.org/10.1136/bmj.k5301

Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C; Block GA; Boudville NC; Campbell K; Cameron JD; Chen SSM; Faull RJ; Holt SG; Hooi LS; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Morrish A; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Badve S, 2019, 'Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction on Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study', BMJ Open, 9, pp. e024382, http://dx.doi.org/10.1136/bmjopen-2018-024382

Zhou Z; Lindley RI; Rådholm K; Jenkins B; Watson J; Perkovic V; Mahaffey KW; De Zeeuw D; Fulcher G; Shaw W; Oh R; Desai M; Matthews DR; Neal B, 2019, 'Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results from the Randomized CANVAS Program Trials', Stroke, 50, pp. 396 - 404, http://dx.doi.org/10.1161/STROKEAHA.118.023009

Neuen BL; Ohkuma T; Neal B; Matthews DR; De Zeeuw D; Mahaffey KW; Fulcher G; Li Q; Jardine M; Oh R; Heerspink HL; Perkovic V, 2019, 'Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: Data from the CANVAS program', Journal of the American Society of Nephrology, 30, pp. 2229 - 2242, http://dx.doi.org/10.1681/ASN.2019010064

Rosenstock J; Perkovic V; Johansen OE; Cooper ME; Kahn SE; Marx N; Alexander JH; Pencina M; Toto RD; Wanner C; Zinman B; Woerle HJ; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; Von Eynatten M; McGuire DK, 2019, 'Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial', JAMA - Journal of the American Medical Association, 321, pp. 69 - 79, http://dx.doi.org/10.1001/jama.2018.18269

Smyth B; Krishnan AV; Gallagher M; Kiernan M; Snelling P; Hawley C; Fernando M; Hand S; Grimley K; Burman J; Heath A; Kang A; Perkovic V; Jardine MJ, 2019, 'Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol', BMJ Open, 9, pp. bmjopen-2018-023736, http://dx.doi.org/10.1136/bmjopen-2018-023736

Bello AK; Levin A; Lunney M; Osman MA; Ye F; Ashuntantang GE; Bellorin-Font E; Benghanem Gharbi M; Davison SN; Ghnaimat M; Harden P; Htay H; Jha V; Kalantar-Zadeh K; Kerr PG; Klarenbach S; Kovesdy CP; Luyckx VA; Neuen BL; O'Donoghue D; Ossareh S; Perl J; Rashid HU; Rondeau E; See E; Saad S; Sola L; Tchokhonelidze I; Tesar V; Tungsanga K; Turan Kazancioglu R; Wang AYM; Wiebe N; Yang CW; Zemchenkov A; Zhao MH; Jager KJ; Caskey F; Perkovic V; Jindal KK; Okpechi IG; Tonelli M; Feehally J; Harris DC; Johnson DW, 2019, 'Status of care for end stage kidney disease in countries and regions worldwide: International cross sectional survey', The BMJ, 367, http://dx.doi.org/10.1136/bmj.l5873

Neuen B; Heerspink H; Neal B; Matthews D; de Zeeuw D; Mahaffey K; Davidson J; Jardine M; Zoungas S; Perkovic V, 2019, 'Abstract #259 Cardiovascular and Renal Outcomes with Canagliflozin in People with Type 2 Diabetes According to Baseline use of Metformin', Endocrine Practice, 25, pp. 99 - 100, http://dx.doi.org/10.1016/s1530-891x(20)46603-0

Toto R; Perkovic V; Johansen OE; Cooper M; Rosenstock J; Kahn S; Marx N; Alexander JH; George J; Zinman B, 2019, 'Abstract #289 Effect of Linagliptin on Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes and Kidney Disease: Carmelina®', Endocrine Practice, 25, pp. 117 - 118, http://dx.doi.org/10.1016/s1530-891x(20)46633-9

Figtree G; Rådholm K; Barrett TD; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Matthews DR; Shaw W; Neal B, 2019, 'EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE OUTCOMES WITH AND WITHOUT PRESERVED EJECTION FRACTION IN TYPE 2 DIABETES: RESULTS FROM THE CANVAS PROGRAM', Journal of the American College of Cardiology, 73, pp. 685, http://dx.doi.org/10.1016/s0735-1097(19)31293-8

Smyth B; Haber A; Trongtrakul K; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'SAT-041 A META-ANALYSIS OF THE REPRESENTATIVENESS OF RANDOMIZED CONTROLLED TRIAL COHORTS IN END-STAGE KIDNEY DISEASE', Kidney International Reports, 4, pp. S21 - S21, http://dx.doi.org/10.1016/j.ekir.2019.05.064

OSHIMA M; Jun M; Toyama T; Perkovic V; Chalmers J; Woodward M, 2019, 'SAT-287 eGFR SLOPE AND THE SUBSEQUENT RISK OF CLINICAL OUTCOMES IN TYPE 2 DIABETES', Kidney International Reports, 4, pp. S128 - S128, http://dx.doi.org/10.1016/j.ekir.2019.05.325

Toyama T; NEUEN B; Jun M; Ohkuma T; Neal B; Jardine M; Heerspink H; Ninomiya T; Wada T; Perkovic V, 2019, 'SAT-298 EFFECT OF SGLT2 INHIBITORS ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE', Kidney International Reports, 4, pp. s133, http://dx.doi.org/10.1016/j.ekir.2019.05.338

, 2019, 'When should treatment be started for hypertension?', Aust Prescr, 42, pp. 180 - 181, http://dx.doi.org/10.18773/austprescr.2019.069

Mohammedi K; Chalmers J; Herrington W; Li Q; Mancia G; Marre M; Poulter N; Rodgers A; Williams B; Perkovic V; Coresh J; Woodward M, 2018, 'Associations between body mass index and the risk of renal events in patients with type 2 diabetes', Nutrition and Diabetes, 8, pp. 7, http://dx.doi.org/10.1038/s41387-017-0012-y

de Zeeuw D; Renfurm RW; Bakris G; Rossing P; Perkovic V; Hou FF; Nangaku M; Sharma K; Heerspink HJL; Garcia-Hernandez A; Larsson TE, 2018, 'Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial', The Lancet Diabetes and Endocrinology, 6, pp. 925 - 933, http://dx.doi.org/10.1016/S2213-8587(18)30289-4

Tong A; Manns B; Wang AYM; Hemmelgarn B; Wheeler DC; Gill J; Tugwell P; Pecoits-Filho R; Crowe S; Harris T; Van Biesen W; Winkelmayer WC; Levin A; Thompson A; Perkovic V; Ju A; Gutman T; Bernier-Jean A; Viecelli AK; O'Lone E; Shen J; Josephson MA; Cho Y; Johnson DW; Sautenet B; Tonelli M; Craig JC; Sinha A; Ong A; Denny A; Dart A; Eddy A; Kelly A; Davenport A; Narva A; Sharma A; Warrens A; Chapman A; Teixeira-Pinto A; Murphy B; Padilla B; Canaud B; Pullin B; Schiller B; Robinson B; Hanson C; Hawley C; Logeman C; Lok C; Wanner C; Herzog C; Rutherford C; Ahn C; Sumpton D; Rosenbloom D; Harris D; Baron D; White D; Gipson D; Fouque D; Eilers D; Bockenhauer D; O'Donoghue D; Chen D; Dunning D; Brown E; Bavlovlenkov E; Mannon E; Poggio E; Chemla E; Dobbels F; Zannad F; Caskey F; Tentori F; Hurst F; Schaefer F; Wong G; Brunier G; Strippoli G; Rangan G; Knoll G; Obrador G; Feldman H; Coolican H; Yap HK; Groothoff J; Sloand J; Tan J; Locke J; Perl J; Chapman J; Dong J; Malyszko J; Fox J; Dapueto J; Tze-Wah Kao J; Chow KM; Manera K; Azukaitis K; Polkinghorne K, 2018, 'Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop', Kidney International, 94, pp. 1053 - 1068, http://dx.doi.org/10.1016/j.kint.2018.08.018

Wong MG; Jardine M; Perkovic V, 2018, 'Glucose lowering and the kidney: are all drug classes equal?', The Lancet Diabetes and Endocrinology, 6, pp. 835 - 837, http://dx.doi.org/10.1016/S2213-8587(18)30291-2

Neuen BL; Perkovic V, 2018, 'Reducing cardiovascular risk in people with diabetes and kidney disease', Medical Journal of Australia, 209, pp. 438 - 439, http://dx.doi.org/10.5694/MJA18.00929

Heerspink HJL; List J; Perkovic V, 2018, 'New clinical trial designs for establishing drug efficacy and safety in a precision medicine era', Diabetes, Obesity and Metabolism, 20, pp. 14 - 18, http://dx.doi.org/10.1111/dom.13417

Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S, 2018, 'Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease', Cochrane Database of Systematic Reviews, 2018, http://dx.doi.org/10.1002/14651858.CD011798.pub2

Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B, 2018, 'Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials', The Lancet Diabetes and Endocrinology, 6, pp. 691 - 704, http://dx.doi.org/10.1016/S2213-8587(18)30141-4

Matthews DR; Perkovic V; Mahaffey KW, 2018, 'Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"', Circulation, 138, pp. 660 - 661, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035717

Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Yi T; Parving HH; de Zeeuw D, 2018, 'Baseline characteristics and enrichment results from the SONAR trial', Diabetes, Obesity and Metabolism, 20, pp. 1829 - 1835, http://dx.doi.org/10.1111/dom.13315

Neuen BL; Ohkuma T; Neal B; Matthews DR; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine M; Bakris G; Perkovic V, 2018, 'Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease', DIABETES, 67, http://dx.doi.org/10.2337/db18-258-OR

Heerspink HJL; Perkovic V, 2018, 'Trial design innovations to accelerate therapeutic advances in chronic kidney disease: Moving from single trials to an ongoing platform', Clinical Journal of the American Society of Nephrology, 13, pp. 946 - 948, http://dx.doi.org/10.2215/CJN.01290118

Rådholm K; Wu JH; Wong MG; Foote C; Fulcher G; Mahaffey KW; Perkovic V; Neal B, 2018, 'Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review', Diabetes Research and Clinical Practice, 140, pp. 118 - 128, http://dx.doi.org/10.1016/j.diabres.2018.03.027

Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Parving HH; de Zeeuw D, 2018, 'Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy', Diabetes, Obesity and Metabolism, 20, pp. 1369 - 1376, http://dx.doi.org/10.1111/dom.13245

de Zeeuw D; Heerspink HJL; Jardine M; Perkovic V, 2018, 'Renal trials in diabetes need a platform: time for a global approach?', The Lancet Diabetes and Endocrinology, 6, pp. 356 - 358, http://dx.doi.org/10.1016/S2213-8587(17)30263-2

Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK, 2018, 'Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA^®): A randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk', Cardiovascular Diabetology, 17, http://dx.doi.org/10.1186/s12933-018-0682-3

Pecoits-Filho R; Perkovic V, 2018, 'Are SGLT2 inhibitors ready for prime time for CKD?', Clinical Journal of the American Society of Nephrology, 13, pp. 318 - 320, http://dx.doi.org/10.2215/CJN.07680717

Okpechi IG; Alrukhaimi M; Ashuntantang GE; Bellorin-Font E; Benghanem Gharbi M; Braam B; Feehally J; Harris DC; Jha V; Jindal K; Johnson DW; Kalantar-Zadeh K; Kazancioglu R; Levin A; Lunney M; Olanrewaju TO; Perkovic V; Perl J; Rashid HU; Rondeau E; Salako BL; Samimi A; Sola L; Tchokhonelidze I; Wiebe N; Yang CW; Ye F; Zemchenkov A; Zhao MH; Bello AK, 2018, 'Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology', Kidney International Supplements, 8, pp. 82 - 89, http://dx.doi.org/10.1016/j.kisu.2017.10.012

Mahaffey KW; Neal B; Perkovic V; De Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR, 2018, 'Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)', Circulation, 137, pp. 323 - 334, http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038

Wong MG; Heerspink HJL; Perkovic V, 2018, 'ACCORDION: Ensuring that we hear the music clearly', Clinical Journal of the American Society of Nephrology, 13, pp. 1621 - 1623, http://dx.doi.org/10.2215/CJN.11370918

Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; De Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B, 2018, 'Canagliflozin and heart failure in type 2 diabetes mellitus: Results from the CANVAS program', Circulation, 138, pp. 458 - 468, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034222

Neuen BL; Ohkuma T; Neal B; Matthews DR; De Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V, 2018, 'Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function data from the CANVAS program', Circulation, 138, pp. 1537 - 1550, http://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901

Jun M; Ohkuma T; Zoungas S; Colagiuri S; Mancia G; Marre M; Matthews D; Poulter N; Williams B; Rodgers A; Perkovic V; Chalmers J; Woodward M, 2018, 'Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from ADVANCE-ON', Diabetes Care, 41, pp. 163 - 170, http://dx.doi.org/10.2337/dc17-1467

Smyth B; Perkovic V, 2018, 'New hypoglycemic agents and the kidney: What do the major trials tell us?.', F1000Research, 7, http://dx.doi.org/10.12688/f1000research.16135.1

Jardine MJ; Mahaffey KW; Neal B; Agarwal R; Bakris GL; Brenner BM; Bull S; Cannon CP; Charytan DM; De Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Pollock C; Wheeler DC; Xie J; Zhang H; Zinman B; Desai M; Perkovic V, 2018, 'The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics', American Journal of Nephrology, 46, pp. 462 - 472, http://dx.doi.org/10.1159/000484633

Ovalle F; Dumas R; Fabbrini E; Slee A; Perkovic V, 2018, 'Abstract #233 Outcomes with Canagliflozin in Patients By Age Subgroups: Results from the Canvas Program', Endocrine Practice, 24, pp. 45 - 45, http://dx.doi.org/10.1016/s1530-891x(20)47079-x

Neal B; Perkovic V; Matthews DR, 2017, 'Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes Reply', NEW ENGLAND JOURNAL OF MEDICINE, 377, pp. 2099 - 2099

Neal B; Perkovic V; Matthews DR, 2017, 'The authors reply', New England Journal of Medicine, 377, pp. 2099, http://dx.doi.org/10.1056/NEJMc1712572

Groop PH; Cooper ME; Perkovic V; Hocher B; Kanasaki K; Haneda M; Schernthaner G; Sharma K; Stanton RC; Toto R; Cescutti J; Gordat M; Meinicke T; Koitka-Weber A; Thiemann S; von Eynatten M, 2017, 'Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial', Diabetes, Obesity and Metabolism, 19, pp. 1610 - 1619, http://dx.doi.org/10.1111/dom.13041

Levin A; Tonelli M; Bonventre J; Coresh J; Donner JA; Fogo AB; Fox CS; Gansevoort RT; Heerspink HJL; Jardine M; Kasiske B; Köttgen A; Kretzler M; Levey AS; Luyckx VA; Mehta R; Moe O; Obrador G; Pannu N; Parikh CR; Perkovic V; Pollock C; Stenvinkel P; Tuttle KR; Wheeler DC; Eckardt KU; Adu D; Agarwal SK; Alrukhaimi M; Anders HJ; Ashuntantang G; Basnet S; Bello AK; Chailimpamontree W; Correa-Rotter R; Craig J; Douthat WG; Feldman HI; Ganji MR; Garcia-Garcia G; Gharbi MB; Harris DC; Jha V; Johnson DW; Kazancioglu R; Langham R; Liu ZH; Massy ZA; Nangaku M; Nelson RG; O'Donoghue D; Okpechi I; Pecoits-Filho R; Powe NR; Remuzzi G; Roberts C; Rossert J; Sola L; Stengel B; M EKS; Suzuki Y; Tanaka T; Tatiyanupanwong S; Thomas B; Uhlig K; Walker R; White SL; Wiecek A; Yang CW, 2017, 'Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy', The Lancet, 390, pp. 1888 - 1917, http://dx.doi.org/10.1016/S0140-6736(17)30788-2

Back to profile page